← FDA Drug Approvals (Drugs@FDA)

REMODULIN

NDA · New Drug Application · Sponsor: UNITED THERAP · Approved 2018-07-30

Drug application

FDA Application #

NDA208276

Application type

New Drug Application

Brand name

REMODULIN

Generic name

Treprostinil

Active ingredients

TREPROSTINIL

Dosage form

SOLUTION

Route

INTRAVENOUS, SUBCUTANEOUS

Marketing status

Discontinued

Sponsor

UNITED THERAP

First approval

2018-07-30

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown